APO Research
Talk to an analyst

APO RESEARCH · REPORT

Erythropoietin

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.

In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml

Selected research

Market Outlook & Growth Opportunities

Global Erythropoietin Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchErythropoietin Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Erythropoietin Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Erythropoietin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Erythropoietin Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Erythropoietin Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.

In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml

Read the full market overview

The major players in global Erythropoietin market include Amgen, Johnson & Johnson, etc. The top 2 players occupy about 60% shares of the global market. North America is the main market, and occupies over 65% of the global market. Epoetin-alfa is the main type, with a share about 80%. Kidney Disorders is the key application, which holds a share over 40%.

This report provides an overview of the global Erythropoietin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Erythropoietin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Erythropoietin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Erythropoietin market size, projected growth trends, production technologies, key applications, and end-use industries.

Erythropoietin Segment by Company

Amgen

Johnson & Johnson

Roche

Galenica

Emcure

Kyowa Hakko Kirin

3SBio

Biocon

LG Life Sciences

Erythropoietin Segment by Type

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

Erythropoietin Segment by Application

Anemia

Kidney Disorders

Others

Erythropoietin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Erythropoietin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Erythropoietin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Erythropoietin significant trends, drivers, influence factors in global and regions.

6. To analyze Erythropoietin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Erythropoietin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Erythropoietin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Erythropoietin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Erythropoietin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Erythropoietin industry.

Chapter 3: Detailed analysis of Erythropoietin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Erythropoietin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Erythropoietin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Erythropoietin Industry Trends Table 2. Erythropoietin Industry Drivers Table 3. Erythropoietin Industry Opportunities and Challenges Table 4. Erythropoietin Industry Restraints Table 5. Global Erythropoietin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Erythropoietin Revenue Share by Company (2021-2026) Table 7. Global Erythropoietin Sales Volume by Company (M Units) & (2021-2026) Table 8. Global Erythropoietin Sales Volume Share by Company (2021-2026) Table 9. Global Erythropoietin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Erythropoietin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Erythropoietin Key Company Manufacturing Base & Headquarters Table 12. Global Erythropoietin Company, Product Type & Application Table 13. Global Erythropoietin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Erythropoietin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Epoetin-alfa Table 18. Significant Companies of Epoetin-beta Table 19. Significant Companies of Darbepoetin-alfa Table 20. Significant Companies of Others Table 21. Global Erythropoietin Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 22. Global Erythropoietin Sales Volume by Type (2021-2026) & (M Units) Table 23. Global Erythropoietin Sales Volume by Type (2027-2032) & (M Units) Table 24. Global Erythropoietin Sales Volume Share by Type (2021-2026) Table 25. Global Erythropoietin Sales Volume Share by Type (2027-2032) Table 26. Global Erythropoietin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Erythropoietin Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Erythropoietin Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Erythropoietin Sales Value Share by Type (2021-2026) Table 30. Global Erythropoietin Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Anemia Table 32. Significant Companies of Kidney Disorders Table 33. Significant Companies of Others Table 34. Global Erythropoietin Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 35. Global Erythropoietin Sales Volume by Application (2021-2026) & (M Units) Table 36. Global Erythropoietin Sales Volume by Application (2027-2032) & (M Units) Table 37. Global Erythropoietin Sales Volume Share by Application (2021-2026) Table 38. Global Erythropoietin Sales Volume Share by Application (2027-2032) Table 39. Global Erythropoietin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Erythropoietin Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Erythropoietin Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Erythropoietin Sales Value Share by Application (2021-2026) Table 43. Global Erythropoietin Sales Value Share by Application (2027-2032) Table 44. Global Erythropoietin Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 45. Global Erythropoietin Sales by Region (2021-2026) & (M Units) Table 46. Global Erythropoietin Sales Market Share by Region (2021-2026) Table 47. Global Erythropoietin Sales by Region (2027-2032) & (M Units) Table 48. Global Erythropoietin Sales Market Share by Region (2027-2032) Table 49. Global Erythropoietin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Erythropoietin Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Erythropoietin Sales Value Share by Region (2021-2026) Table 52. Global Erythropoietin Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Erythropoietin Sales Value Share by Region (2027-2032) Table 54. Global Erythropoietin Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Erythropoietin Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Erythropoietin Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 57. Global Erythropoietin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Erythropoietin Sales by Country (2021-2026) & (M Units) Table 59. Global Erythropoietin Sales Market Share by Country (2021-2026) Table 60. Global Erythropoietin Sales by Country (2027-2032) & (M Units) Table 61. Global Erythropoietin Sales Market Share by Country (2027-2032) Table 62. Global Erythropoietin Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Erythropoietin Sales Value Market Share by Country (2021-2026) Table 64. Global Erythropoietin Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Erythropoietin Sales Value Market Share by Country (2027-2032) Table 66. Amgen Company Information Table 67. Amgen Business Overview Table 68. Amgen Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Amgen Erythropoietin Product Portfolio Table 70. Amgen Recent Development Table 71. Johnson & Johnson Company Information Table 72. Johnson & Johnson Business Overview Table 73. Johnson & Johnson Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Johnson & Johnson Erythropoietin Product Portfolio Table 75. Johnson & Johnson Recent Development Table 76. Roche Company Information Table 77. Roche Business Overview Table 78. Roche Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Roche Erythropoietin Product Portfolio Table 80. Roche Recent Development Table 81. Galenica Company Information Table 82. Galenica Business Overview Table 83. Galenica Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Galenica Erythropoietin Product Portfolio Table 85. Galenica Recent Development Table 86. Emcure Company Information Table 87. Emcure Business Overview Table 88. Emcure Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Emcure Erythropoietin Product Portfolio Table 90. Emcure Recent Development Table 91. Kyowa Hakko Kirin Company Information Table 92. Kyowa Hakko Kirin Business Overview Table 93. Kyowa Hakko Kirin Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Kyowa Hakko Kirin Erythropoietin Product Portfolio Table 95. Kyowa Hakko Kirin Recent Development Table 96. 3SBio Company Information Table 97. 3SBio Business Overview Table 98. 3SBio Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. 3SBio Erythropoietin Product Portfolio Table 100. 3SBio Recent Development Table 101. Biocon Company Information Table 102. Biocon Business Overview Table 103. Biocon Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Biocon Erythropoietin Product Portfolio Table 105. Biocon Recent Development Table 106. LG Life Sciences Company Information Table 107. LG Life Sciences Business Overview Table 108. LG Life Sciences Erythropoietin Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. LG Life Sciences Erythropoietin Product Portfolio Table 110. LG Life Sciences Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Erythropoietin Distributors List Table 114. Erythropoietin Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Erythropoietin Product Image Figure 2. Global Erythropoietin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Erythropoietin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Erythropoietin Sales (2021-2032) & (M Units) Figure 5. Global Erythropoietin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Erythropoietin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Epoetin-alfa Image Figure 10. Epoetin-beta Image Figure 11. Darbepoetin-alfa Image Figure 12. Others Image Figure 13. Global Erythropoietin Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 14. Global Erythropoietin Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Erythropoietin Sales Volume Share by Type (2021-2032) Figure 16. Global Erythropoietin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Erythropoietin Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Erythropoietin Sales Value Share by Type (2021-2032) Figure 19. Anemia Image Figure 20. Kidney Disorders Image Figure 21. Others Image Figure 22. Global Erythropoietin Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 23. Global Erythropoietin Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Erythropoietin Sales Volume Share by Application (2021-2032) Figure 25. Global Erythropoietin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Erythropoietin Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Erythropoietin Sales Value Share by Application (2021-2032) Figure 28. Global Erythropoietin Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 29. Global Erythropoietin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Erythropoietin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Erythropoietin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Erythropoietin Sales Value (2021-2032) & (US$ Million) Figure 33. North America Erythropoietin Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Erythropoietin Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Erythropoietin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Erythropoietin Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Erythropoietin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Erythropoietin Sales Value (2021-2032) & (US$ Million) Figure 39. South America Erythropoietin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Erythropoietin Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Erythropoietin Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Erythropoietin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Erythropoietin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Erythropoietin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Erythropoietin Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Erythropoietin Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others
Applications
  • Anemia
  • Kidney Disorders
  • Others
Companies covered
  • Amgen
  • Johnson & Johnson
  • Roche
  • Galenica
  • Emcure
  • Kyowa Hakko Kirin
  • 3SBio
  • Biocon
  • LG Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Erythropoietin Sales Value (2021-2032)
  4. 1.2.2 Global Erythropoietin Sales Volume (2021-2032)
  5. 1.2.3 Global Erythropoietin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Erythropoietin Market Dynamics
  1. 2.1 Erythropoietin Industry Trends
  2. 2.2 Erythropoietin Industry Drivers
  3. 2.3 Erythropoietin Industry Opportunities and Challenges
  4. 2.4 Erythropoietin Industry Restraints
3 Erythropoietin Market by Company
  1. 3.1 Global Erythropoietin Company Revenue Ranking in 2025
  2. 3.2 Global Erythropoietin Revenue by Company (2021-2026)
  3. 3.3 Global Erythropoietin Sales Volume by Company (2021-2026)
  4. 3.4 Global Erythropoietin Average Price by Company (2021-2026)
  5. 3.5 Global Erythropoietin Company Ranking (2024-2026)
  6. 3.6 Global Erythropoietin Company Manufacturing Base and Headquarters
  7. 3.7 Global Erythropoietin Company Product Type and Application
  8. 3.8 Global Erythropoietin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Erythropoietin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Erythropoietin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Erythropoietin Market by Type
  1. 4.1 Erythropoietin Type Introduction
  2. 4.1.1 Epoetin-alfa
  3. 4.1.2 Epoetin-beta
  4. 4.1.3 Darbepoetin-alfa
  5. 4.1.4 Others
  6. 4.2 Global Erythropoietin Sales Volume by Type
  7. 4.2.1 Global Erythropoietin Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Erythropoietin Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Erythropoietin Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Erythropoietin Sales Value by Type
  11. 4.3.1 Global Erythropoietin Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Erythropoietin Sales Value by Type (2021-2032)
  13. 4.3.3 Global Erythropoietin Sales Value Share by Type (2021-2032)
5 Erythropoietin Market by Application
  1. 5.1 Erythropoietin Application Introduction
  2. 5.1.1 Anemia
  3. 5.1.2 Kidney Disorders
  4. 5.1.3 Others
  5. 5.2 Global Erythropoietin Sales Volume by Application
  6. 5.2.1 Global Erythropoietin Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Erythropoietin Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Erythropoietin Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Erythropoietin Sales Value by Application
  10. 5.3.1 Global Erythropoietin Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Erythropoietin Sales Value by Application (2021-2032)
  12. 5.3.3 Global Erythropoietin Sales Value Share by Application (2021-2032)
6 Erythropoietin Regional Sales and Value Analysis
  1. 6.1 Global Erythropoietin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Erythropoietin Sales by Region (2021-2032)
  3. 6.2.1 Global Erythropoietin Sales by Region: 2021-2026
  4. 6.2.2 Global Erythropoietin Sales by Region (2027-2032)
  5. 6.3 Global Erythropoietin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Erythropoietin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Erythropoietin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Erythropoietin Sales Value by Region (2027-2032)
  9. 6.5 Global Erythropoietin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Erythropoietin Sales Value (2021-2032)
  12. 6.6.2 North America Erythropoietin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Erythropoietin Sales Value (2021-2032)
  15. 6.7.2 Europe Erythropoietin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Erythropoietin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Erythropoietin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Erythropoietin Sales Value (2021-2032)
  21. 6.9.2 South America Erythropoietin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Erythropoietin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Erythropoietin Sales Value Share by Country, 2025 VS 2032
7 Erythropoietin Country-level Sales and Value Analysis
  1. 7.1 Global Erythropoietin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Erythropoietin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Erythropoietin Sales by Country (2021-2032)
  4. 7.3.1 Global Erythropoietin Sales by Country (2021-2026)
  5. 7.3.2 Global Erythropoietin Sales by Country (2027-2032)
  6. 7.4 Global Erythropoietin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Erythropoietin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Erythropoietin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Erythropoietin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Erythropoietin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Erythropoietin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Erythropoietin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Erythropoietin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Erythropoietin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Erythropoietin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Erythropoietin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Erythropoietin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Erythropoietin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Erythropoietin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Erythropoietin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Erythropoietin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Erythropoietin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Erythropoietin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Erythropoietin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Erythropoietin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Erythropoietin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Erythropoietin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Erythropoietin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Erythropoietin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Erythropoietin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Erythropoietin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Erythropoietin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Erythropoietin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Erythropoietin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Erythropoietin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Erythropoietin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Erythropoietin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Erythropoietin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Erythropoietin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Erythropoietin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Erythropoietin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Erythropoietin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Erythropoietin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Erythropoietin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Erythropoietin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Erythropoietin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Erythropoietin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Erythropoietin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Erythropoietin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Erythropoietin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Erythropoietin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Erythropoietin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Erythropoietin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Erythropoietin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Erythropoietin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Erythropoietin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Erythropoietin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Erythropoietin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Erythropoietin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Erythropoietin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Erythropoietin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Erythropoietin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Erythropoietin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Erythropoietin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Erythropoietin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Erythropoietin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Erythropoietin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Erythropoietin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Erythropoietin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Erythropoietin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Erythropoietin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Erythropoietin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Erythropoietin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Erythropoietin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Erythropoietin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Erythropoietin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Erythropoietin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Erythropoietin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Erythropoietin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Erythropoietin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Erythropoietin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Erythropoietin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Erythropoietin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Erythropoietin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Erythropoietin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Erythropoietin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Erythropoietin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Erythropoietin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Erythropoietin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Erythropoietin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Erythropoietin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Erythropoietin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen Erythropoietin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Amgen Erythropoietin Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Erythropoietin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Erythropoietin Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Erythropoietin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Roche Erythropoietin Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Galenica
  20. 8.4.1 Galenica Company Information
  21. 8.4.2 Galenica Business Overview
  22. 8.4.3 Galenica Erythropoietin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Galenica Erythropoietin Product Portfolio
  24. 8.4.5 Galenica Recent Developments
  25. 8.5 Emcure
  26. 8.5.1 Emcure Company Information
  27. 8.5.2 Emcure Business Overview
  28. 8.5.3 Emcure Erythropoietin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Emcure Erythropoietin Product Portfolio
  30. 8.5.5 Emcure Recent Developments
  31. 8.6 Kyowa Hakko Kirin
  32. 8.6.1 Kyowa Hakko Kirin Company Information
  33. 8.6.2 Kyowa Hakko Kirin Business Overview
  34. 8.6.3 Kyowa Hakko Kirin Erythropoietin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kyowa Hakko Kirin Erythropoietin Product Portfolio
  36. 8.6.5 Kyowa Hakko Kirin Recent Developments
  37. 8.7 3SBio
  38. 8.7.1 3SBio Company Information
  39. 8.7.2 3SBio Business Overview
  40. 8.7.3 3SBio Erythropoietin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 3SBio Erythropoietin Product Portfolio
  42. 8.7.5 3SBio Recent Developments
  43. 8.8 Biocon
  44. 8.8.1 Biocon Company Information
  45. 8.8.2 Biocon Business Overview
  46. 8.8.3 Biocon Erythropoietin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biocon Erythropoietin Product Portfolio
  48. 8.8.5 Biocon Recent Developments
  49. 8.9 LG Life Sciences
  50. 8.9.1 LG Life Sciences Company Information
  51. 8.9.2 LG Life Sciences Business Overview
  52. 8.9.3 LG Life Sciences Erythropoietin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 LG Life Sciences Erythropoietin Product Portfolio
  54. 8.9.5 LG Life Sciences Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Erythropoietin Value Chain Analysis
  2. 9.1.1 Erythropoietin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Erythropoietin Sales Mode & Process
  6. 9.2 Erythropoietin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Erythropoietin Distributors
  9. 9.2.3 Erythropoietin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst